Prevail Therapeutics Inc. (CIK: 0001714798) EDGAR, Information, Filings... CompaniesBIO.Com

Prevail Therapeutics Inc.

Mailing address
430 EAST 29TH STREET, SUITE 940, NEW YORK, Delaware, 10016
Phone
917-336-9310
State location
New York
State of incorporation
Delaware
Fiscal year end
December 31
SIC
2836 - (CF Office: Office of Life Sciences) BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Filings
N/A

Prevail Therapeutics Inc. (CIK: 0001714798) is an American company incorporated in the state of New York. Head office is located at 430 EAST 29TH STREET, SUITE 940, NEW YORK, New York, 10016. Work in the industry 2836 - (CF Office: Office of Life Sciences) BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES). Prevail Therapeutics Inc. is a public company and trade via Over-The-Counter (OTC).

Owner	Filings	Transaction Date	Type of Owner
ELI LILLY & Co	0000059478	Dec-14-2020	10 percent owner
Tyto Acquisition Corp	0001836675	Dec-14-2020	10 percent owner
Carson William H.	0001824280	Sep-09-2020	director
Schwartz Kira M.	0001813735	Jun-01-2020	officer: General Counsel
Sheng Morgan	0001793833	Nov-15-2019	director
ORBIMED ADVISORS LLC	0001055951	Jun-19-2019	director, 10 percent owner
GORDON CARL L	0001282930	Jun-19-2019	director, 10 percent owner
Adams Timothy M	0001298669	Jun-19-2019	director
Thompson Peter A.	0001357522	Jun-19-2019	director, 10 percent owner
Nader Francois	0001365343	Jun-19-2019	director
Nussbaum Ran	0001609805	Jun-19-2019	director
OrbiMed Capital GP VI LLC	0001682115	Jun-19-2019	director, 10 percent owner
Hefti Franz	0001735529	Jun-19-2019	officer: Chief Development Officer
Abeliovich Asa	0001778476	Jun-19-2019	director, 10 percent owner, officer: President & CEO
Sevigny Jeffrey	0001778483	Jun-19-2019	officer: Chief Medical Officer
Dai Yong	0001778488	Jun-19-2019	officer: Chief Technology Officer
Minkow Emily	0001778491	Jun-19-2019	officer: Chief Business Officer
Kaplan Brett	0001778763	Jun-19-2019	officer: Chief Financial Officer

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Prevail Therapeutics Inc.

Filings	Format	Description	Filed/Effective	File/Film Number
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001104659-21-024244 (34 Act) Size: 71 KB	Feb-16-2021	005-91049 21639689
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001104659-21-024136 (34 Act) Size: 156 KB	Feb-16-2021	005-91049 21639221
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001193125-21-041576 (34 Act) Size: 46 KB	Feb-12-2021	005-91049 21627740
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0000935836-21-000106 (34 Act) Size: 45 KB	Feb-12-2021	005-91049 21627224
15-12B	Document	Notice of termination of registration of a class of securities under Section 12(b) Acc-no: 0001193125-21-023611 (34 Act) Size: 11 KB	Feb-01-2021	001-38939 21574278
SC 13G	Document	Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001123292-21-000143 (34 Act) Size: 201 KB	Jan-29-2021	005-91049 21571348
SC 13D/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities Acc-no: 0000947871-21-000118 (34 Act) Size: 74 KB	Jan-29-2021	005-91049 21567486
EFFECT	Document	Acc-no: 9999999995-21-000278 (33 Act) Size: 1 KB	Jan-26-2021	333-239612 21556610
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001209191-21-005464 ( Act) Size: 8 KB	Jan-26-2021
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001209191-21-005459 ( Act) Size: 12 KB	Jan-26-2021
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001209191-21-005455 ( Act) Size: 8 KB	Jan-26-2021
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001209191-21-005449 ( Act) Size: 6 KB	Jan-26-2021
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001209191-21-005442 ( Act) Size: 10 KB	Jan-26-2021
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001209191-21-005438 ( Act) Size: 10 KB	Jan-26-2021
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001209191-21-005435 ( Act) Size: 10 KB	Jan-26-2021
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001209191-21-005432 ( Act) Size: 14 KB	Jan-26-2021
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001209191-21-005429 ( Act) Size: 12 KB	Jan-26-2021
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001209191-21-005423 ( Act) Size: 6 KB	Jan-26-2021
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001209191-21-005418 ( Act) Size: 10 KB	Jan-26-2021
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001209191-21-005411 ( Act) Size: 8 KB	Jan-26-2021

Recent 20 filings. View all Prevail Therapeutics Inc. filings

Overall rating 5.0

Aug 22, 2022

Pelisari

young lad who new his job ansered questions and new what was best for me.

Aug 22, 2022

Ryan Storey

Huge help thank you for your help .. y'all make it so much easier

Aug 22, 2022

Jean Bishop

Very good communication and delivery made within the timeframe I was advised of

Prevail Therapeutics Inc. overview
Prevail Therapeutics Inc. job
Prevail Therapeutics Inc. stock
Prevail Therapeutics Inc. ownership
Prevail Therapeutics Inc. CEO
Prevail Therapeutics Inc. documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.